AR084498A1 - Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson - Google Patents

Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson

Info

Publication number
AR084498A1
AR084498A1 ARP110104270A ARP110104270A AR084498A1 AR 084498 A1 AR084498 A1 AR 084498A1 AR P110104270 A ARP110104270 A AR P110104270A AR P110104270 A ARP110104270 A AR P110104270A AR 084498 A1 AR084498 A1 AR 084498A1
Authority
AR
Argentina
Prior art keywords
apomorphine
kits
combinations
methods
parkinson
Prior art date
Application number
ARP110104270A
Other languages
English (en)
Spanish (es)
Inventor
Frazer Giles Morgan
Mark Jonathan Main
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1019291.2A external-priority patent/GB201019291D0/en
Priority claimed from GBGB1101924.7A external-priority patent/GB201101924D0/en
Priority claimed from GBGB1107454.9A external-priority patent/GB201107454D0/en
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of AR084498A1 publication Critical patent/AR084498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP110104270A 2010-11-15 2011-11-16 Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson AR084498A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1019291.2A GB201019291D0 (en) 2010-11-15 2010-11-15 Compositions and uses
GBGB1101924.7A GB201101924D0 (en) 2011-02-04 2011-02-04 Compositions and uses
GBGB1107454.9A GB201107454D0 (en) 2011-05-05 2011-05-05 Compositions and uses

Publications (1)

Publication Number Publication Date
AR084498A1 true AR084498A1 (es) 2013-05-22

Family

ID=45099135

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104270A AR084498A1 (es) 2010-11-15 2011-11-16 Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson

Country Status (6)

Country Link
US (1) US20130287854A1 (enExample)
EP (1) EP2640374A1 (enExample)
JP (1) JP2013542246A (enExample)
AR (1) AR084498A1 (enExample)
TW (1) TW201304822A (enExample)
WO (1) WO2012066319A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394942B (es) * 2012-10-22 2025-03-24 Merz Pharmaceuticals Llc Variabilidad reductora entre pacientes de concentraciones plasmaticas de levodopa
MX372641B (es) 2012-10-22 2020-06-15 Merz Pharmaceuticals Llc Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US20140377189A1 (en) * 2013-06-19 2014-12-25 Map Pharmaceuticals, Inc. Pulmonary administration of rotigotine
WO2014205031A1 (en) * 2013-06-19 2014-12-24 Map Pharmaceuticals, Inc. Sustained-release formulation of rotigotine
TWI589308B (zh) 2014-03-25 2017-07-01 林信湧 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法
EP3831375A1 (en) * 2014-04-21 2021-06-09 Civitas Therapeutics, Inc. Rapid relief of motor fluctuations in parkinson's disease
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
US11612613B2 (en) 2017-08-08 2023-03-28 Robert Petcavich Formulations for the delivery of autophagy stimulating Trehalose
JP2021519337A (ja) 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤
EP3823607A4 (en) * 2018-07-19 2022-04-06 Impel NeuroPharma Inc. ADMINISTRATION OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR INTO THE RESPIRATORY TRACT FOR THE TREATMENT OF PARKINSON'S DISEASE
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体ｄ因子の医学的障害の治療のための医薬化合物
EP3840754A4 (en) * 2018-08-23 2022-09-14 Sunovion Pharmaceuticals Inc. ACID ADDITIONAL SALTS OF APOMORPHINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE THEREOF
EP3866773B1 (en) 2018-10-16 2024-08-28 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
MX2021012524A (es) 2019-04-12 2021-11-12 C4 Therapeutics Inc Degradadores triciclicos de ikaros y aiolos.
WO2021127452A1 (en) 2019-12-19 2021-06-24 Georgia State University Research Foundation, Inc. Compounds for the treatment of bacterial infections and potentiation of antibiotics
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
CA3165309A1 (en) 2020-03-05 2021-09-10 Christopher G. Nasveschuk Compounds for targeted degradation of brd9
JP2023538859A (ja) * 2020-08-31 2023-09-12 パーデュー、ファーマ、リミテッド、パートナーシップ レボドパ送達のための組成物及び方法
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0865789B1 (en) 1993-03-26 2005-03-16 Franciscus Wilhelmus Henricus Maria Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
ATE378039T1 (de) 2000-06-27 2007-11-15 Vectura Ltd Herstellungsverfahren für partikel zur verwendung in einer arzneizusammensetzung
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE60132239T2 (de) 2000-11-30 2008-05-08 Vectura Ltd., Claverton Down Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
JP2005506855A (ja) 2001-05-10 2005-03-10 ベクトゥラ デリバリー デバイシーズ リミテッド 吸入器
GB2375308A (en) 2001-05-10 2002-11-13 Cambridge Consultants Inhalers
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20060292081A1 (en) 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
MX2010013393A (es) * 2008-06-06 2011-06-21 Pharma Two B Ltd Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
GB0901520D0 (en) 2009-01-30 2009-03-11 Vectura Delivery Devices Ltd Inhaler

Also Published As

Publication number Publication date
EP2640374A1 (en) 2013-09-25
JP2013542246A (ja) 2013-11-21
US20130287854A1 (en) 2013-10-31
WO2012066319A1 (en) 2012-05-24
TW201304822A (zh) 2013-02-01

Similar Documents

Publication Publication Date Title
AR084498A1 (es) Metodos, combinaciones, apomorfina, kits, usos, capsula y dispositivo de inhalacion para tratar y/o prevenir los sintomas de la enfermedad de parkinson
PE20190914A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
AR084802A1 (es) Agente para mejorar el rendimiento y/o la calidad de la leche, agente para prevenir o tratar enfermedades perinatales y agente para mejorar la reproduccion en los rumiantes
MX2024001203A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con moduladores metabolicos para usarse en tratar enfermedades del higado graso.
BR112013019026A2 (pt) formulações farmacêuticas incluindo um composto amina
CO6410297A2 (es) Tratamiento de trastornos relacionados con la discinesia
EA201290865A1 (ru) Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
CO6731103A2 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
JP2012092127A5 (enExample)
BR112014000843A2 (pt) Uso de picosulfato para preparação de composição intestinal para o cálculo da duração de colonoscopia, composição intestinal e kit
BR112014010586A2 (pt) aditivos para uso na preservação da madeira
BR112014013481A2 (pt) processo para a oxidação de alcanos com o uso de uma alkb alcano 1-mono-oxigenase
CO6630136A2 (es) Procedimiento para la preparación de 4-{4[({4-cloro-3-(trifluorometil) fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carbocamida, sus sales y su monohidrato
EA201391592A1 (ru) Местная композиция для лечения гиперкератотической кожи
AR077514A1 (es) Formulacion recubierta de liquido de pericarpio de castana de caju
MX2022006161A (es) Composicion de extractos naturales con actividad antibacteriana o bacteriostatica tambien para bacterias gram negativas.
JP2017503756A5 (enExample)
AR073525A1 (es) Agente terapeutico contra el meteorismo para un rumiante
AR067432A1 (es) Una composicion de hidroxido de litio, un proceso para su preparacion, y un proceso para su utilizacion
AR074302A1 (es) Trans-clomifeno para el sindrome metabolico y la diabetes mellitus tipo 2.. metodo
WO2014059326A3 (en) Methods of identifying compounds for treating depression and other related diseases
Bi et al. Etudes phytochimique et pharmacologique de Bridelia ferruginea Benth (Euphorbiaceae) sur la motricité du Taenia coli de cobaye
BR112014015277A8 (pt) células-tronco pluripotentes induzidas, preparadas a partir de células derivadas de rim humano
How et al. The effect of atenolol on serum thyroid hormones in hyperthyroid patients
BR112014001184A2 (pt) processo para preparar um composto de fórmula i, processo para preparar um composto de fórmula ii, processo para preparar uma solução de um composto de fórmula iii, e composição

Legal Events

Date Code Title Description
FB Suspension of granting procedure